Van Putten T, May P R, Marder S R, Wilkins J N, Rosenberg B J
Psychopharmacology (Berl). 1983;79(1):40-4. doi: 10.1007/BF00433014.
Thirty-four newly admitted schizophrenic patients were treated with a fixed dose of thiothixene (0.44 mg/kg) for 4 weeks. Thiothixene and its active metabolites were measured by a new radioreceptor assay. Improvement occurred over the entire range of recorded plasma levels, but the chances of substantial improvement appear greater above 40 neuroleptic units (n.u.). The data do not support the notion of a "therapeutic window", in that higher plasma levels were not associated with side effects or clinical deterioration (although at extreme plasma levels this must of course be so). In 11 nonresponders dosage could not be increased because of side effects. If a non-responder with troublesome side effects has a low plasma level (less than 40 n.u.), it would seem prudent to switch to another antipsychotic drug.
34名新入院的精神分裂症患者接受了固定剂量（0.44毫克/千克）的硫利达嗪治疗，为期4周。采用一种新的放射受体分析法测定硫利达嗪及其活性代谢产物。在记录的血浆水平范围内均有改善，但在40个抗精神病单位（n.u.）以上出现显著改善的可能性似乎更大。数据不支持“治疗窗”的概念，因为较高的血浆水平与副作用或临床恶化无关（尽管在极高的血浆水平时肯定会如此）。11名无反应者因副作用无法增加剂量。如果一名有严重副作用的无反应者血浆水平较低（低于40 n.u.），那么换用另一种抗精神病药物似乎是明智的。
